vTv Therapeutics Inc (NASDAQ:VTVT) shot up 10.2% on Friday . The stock traded as high as $1.60 and last traded at $1.51, 486,143 shares were traded during trading. A decline of 33% from the average session volume of 725,455 shares. The stock had previously closed at $1.37.
Several equities analysts have commented on VTVT shares. Zacks Investment Research raised vTv Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research report on Friday. ValuEngine raised vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Northland Securities reaffirmed a “buy” rating on shares of vTv Therapeutics in a research report on Thursday, October 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of vTv Therapeutics in a research report on Friday, August 16th.
The company has a fifty day simple moving average of $1.46 and a two-hundred day simple moving average of $1.45. The firm has a market capitalization of $75.24 million, a PE ratio of -2.19 and a beta of -3.61.
In other news, major shareholder Ronald O. Perelman acquired 1,369,863 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were acquired at an average cost of $1.46 per share, with a total value of $1,999,999.98. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Ronald O. Perelman acquired 50,000 shares of the business’s stock in a transaction dated Thursday, August 22nd. The stock was purchased at an average cost of $1.38 per share, for a total transaction of $69,000.00. The disclosure for this purchase can be found here. Insiders bought 3,550,787 shares of company stock worth $5,273,751 over the last three months. Corporate insiders own 1.70% of the company’s stock.
An institutional investor recently bought a new position in vTv Therapeutics stock. Wedbush Securities Inc. bought a new position in shares of vTv Therapeutics Inc (NASDAQ:VTVT) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 25,100 shares of the biotechnology company’s stock, valued at approximately $39,000. Institutional investors and hedge funds own 1.69% of the company’s stock.
vTv Therapeutics Company Profile (NASDAQ:VTVT)
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.